XI'AN, China, Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ("Skystar", "Company"), a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that its Director & U.S. Representative, Scott Cramer, along with Skystar's Chairman and CEO, Mr. Weibing Lu, Director and Vice General Manager, Mr. Wei Wen will present at the upcoming Roth Capital Partners 2007 New York Conference (the "Roth Conference") on Thursday, September 6, 2007.
The Roth Capital Partners Conference features presentations from more than 230 small- and micro-cap companies with a focus on undiscovered companies as well as international companies that aren't well known to U.S. investors in the technology, healthcare, financial services and consumer products sectors. The date, time and location of Skystar's presentation at the Roth Conference are as follows:
Date: Thursday, September 6, 2007
Time: 3:00 p.m. Eastern Time
Venue: The Westin Times Square Hotel, New York
If you are unable to attend the presentation, you may view the live webcast of the event at http://www.skystarbio-pharmaceutical.com . A replay of the webcast will be available for 90 days following the live event on Skystar’s website, http://www.skystarbio-pharmaceutical.com .
Interested parties and institutional investors may register for the conference by visiting the conference website at http://www.rothconference.com or by calling Roth Capital Partners at 1-800-678-9147 .
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The company recently completed the first phase of construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .
For more information, please contact:
Skystar Bio-Pharmaceutical Co., Ltd
Scott Cramer
Director - U.S. Representative
Tel: +1-407-645-4433
Email: scramer@skystarbio-pharmaceutical.com
CCG Elite Investor Relations
Crocker Coulson
President
Email: crocker.coulson@ccgir.com
Leslie Richardson
Financial Writer
Tel: +1-310-231-8600 x122
Email: leslie.richardson@ccgir.com
